{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T03:04:37Z","timestamp":1787195077197,"version":"build-2736575974"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-73948-x","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T04:01:57Z","timestamp":1728360117000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Presence of cholestasis and its impact on survival in SARS-CoV-2 associated acute respiratory distress syndrome"],"prefix":"10.1038","volume":"14","author":[{"given":"Mathias","family":"Schneeweiss-Gleixner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Krenn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Petter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Haselwanter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Kraft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Semmler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Hartl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emina","family":"Halilbasic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Buchtele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Krall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Staudinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Zauner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Trauner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert Friedrich","family":"St\u00e4ttermayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,8]]},"reference":[{"key":"73948_CR1","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","volume":"8","author":"Z Xu","year":"2020","unstructured":"Xu, Z. et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir. Med. 8, 420\u2013422 (2020).","journal-title":"Lancet Respir. Med."},{"key":"73948_CR2","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","volume":"395","author":"P Mehta","year":"2020","unstructured":"Mehta, P. et al. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet 395, 1033\u20131034 (2020).","journal-title":"Lancet"},{"key":"73948_CR3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/liv.14730","volume":"41","author":"AD Nardo","year":"2021","unstructured":"Nardo, A. D. et al. Pathophysiological mechanisms of liver injury in COVID-19. Liver Int. 41, 20\u201332 (2021).","journal-title":"Liver Int."},{"key":"73948_CR4","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12871-023-02006-2","volume":"23","author":"J Henrie","year":"2023","unstructured":"Henrie, J. et al. Profile of liver cholestatic biomarkers following prolonged ketamine administration in patients with COVID-19. BMC Anesthesiol. 23, 44 (2023).","journal-title":"BMC Anesthesiol."},{"key":"73948_CR5","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/s41575-021-00426-4","volume":"18","author":"T Marjot","year":"2021","unstructured":"Marjot, T. et al. COVID-19 and liver disease: Mechanistic and clinical perspectives. Nat. Rev. Gastroenterol. Hepatol. 18, 348\u2013364 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"73948_CR6","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1111\/apt.15916","volume":"52","author":"AV Kulkarni","year":"2020","unstructured":"Kulkarni, A. V. et al. Systematic review with meta-analysis: Liver manifestations and outcomes in COVID-19. Aliment. Pharmacol. Ther. 52, 584\u2013599 (2020).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"73948_CR7","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1136\/gutjnl-2020-322072","volume":"70","author":"DK Yadav","year":"2021","unstructured":"Yadav, D. K. et al. Involvement of liver in COVID-19: Systematic review and meta-analysis. Gut 70, 807\u2013809 (2021).","journal-title":"Gut"},{"key":"73948_CR8","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s12072-020-10071-9","volume":"14","author":"P Kumar-M","year":"2020","unstructured":"Kumar-M, P. et al. Coronavirus disease (COVID-19) and the liver: A comprehensive systematic review and meta-analysis. Hepatol. Int. 14, 711\u2013722 (2020).","journal-title":"Hepatol. Int."},{"key":"73948_CR9","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1111\/liv.14477","volume":"40","author":"P Paliogiannis","year":"2020","unstructured":"Paliogiannis, P. & Zinellu, A. Bilirubin levels in patients with mild and severe Covid-19: A pooled analysis. Liver Int. 40, 1787\u20131788 (2020).","journal-title":"Liver Int."},{"key":"73948_CR10","doi-asserted-by":"publisher","first-page":"328","DOI":"10.3390\/biomedicines8090328","volume":"8","author":"V Bernal-Monterde","year":"2020","unstructured":"Bernal-Monterde, V. et al. SARS-CoV-2 infection induces a dual response in liver function tests: Association with mortality during hospitalization. Biomedicines 8, 328 (2020).","journal-title":"Biomedicines"},{"key":"73948_CR11","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1007\/s12072-023-10521-0","volume":"17","author":"S Leonhardt","year":"2023","unstructured":"Leonhardt, S. et al. Hepatobiliary long-term consequences of COVID-19: Dramatically increased rate of secondary sclerosing cholangitis in critically ill COVID-19 patients. Hepatol. Int. 17, 1610\u20131625 (2023).","journal-title":"Hepatol. Int."},{"key":"73948_CR12","doi-asserted-by":"publisher","first-page":"e179","DOI":"10.1093\/cid\/ciac565","volume":"76","author":"P Hunyady","year":"2022","unstructured":"Hunyady, P. et al. Secondary sclerosing cholangitis following coronavirus disease 2019 (COVID-19): A multicenter retrospective study. Clin. Infect. Dis. 76, e179\u2013e187 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"73948_CR13","doi-asserted-by":"crossref","unstructured":"Edwards, K., Allison, M. & Ghuman, S. Secondary sclerosing cholangitis in critically ill patients: A rare disease precipitated by severe SARS-CoV-2 infection. BMJ Case Rep. 13 (2020).","DOI":"10.1136\/bcr-2020-237984"},{"key":"73948_CR14","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.14309\/ajg.0000000000001154","volume":"116","author":"NC Roth","year":"2021","unstructured":"Roth, N. C. et al. Post-COVID-19 cholangiopathy: A novel entity. Am. J. Gastroenterol. 116, 1077\u20131082 (2021).","journal-title":"Am. J. Gastroenterol."},{"key":"73948_CR15","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.transproceed.2021.03.007","volume":"53","author":"FA Durazo","year":"2021","unstructured":"Durazo, F. A. et al. Post-covid-19 Cholangiopathy-A new indication for liver transplantation: A case report. Transpl. Proc. 53, 1132\u20131137 (2021).","journal-title":"Transpl. Proc."},{"key":"73948_CR16","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1111\/liv.14971","volume":"41","author":"S Butikofer","year":"2021","unstructured":"Butikofer, S. et al. Secondary sclerosing cholangitis as cause of persistent jaundice in patients with severe COVID-19. Liver Int. 41, 2404\u20132417 (2021).","journal-title":"Liver Int."},{"key":"73948_CR17","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/ncpgasthep0602","volume":"3","author":"A Geier","year":"2006","unstructured":"Geier, A., Fickert, P. & Trauner, M. Mechanisms of disease: Mechanisms and clinical implications of cholestasis in sepsis. Nat. Clin. Pract. Gastroenterol. Hepatol. 3, 574\u2013585 (2006).","journal-title":"Nat. Clin. Pract. Gastroenterol. Hepatol."},{"key":"73948_CR18","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1002\/hep.30824","volume":"70","author":"T Horvatits","year":"2019","unstructured":"Horvatits, T., Drolz, A., Trauner, M. & Fuhrmann, V. Liver injury and failure in critical illness. Hepatology. 70, 2204\u20132215 (2019).","journal-title":"Hepatology"},{"key":"73948_CR19","doi-asserted-by":"publisher","first-page":"e2188","DOI":"10.1097\/MD.0000000000002188","volume":"94","author":"S Leonhardt","year":"2015","unstructured":"Leonhardt, S. et al. Secondary sclerosing cholangitis in critically ill patients: Clinical presentation, cholangiographic features, natural history, and outcome a series of 16 cases. Medicine 94, e2188 (2015).","journal-title":"Medicine"},{"key":"73948_CR20","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13054-015-0861-5","volume":"19","author":"S Leonhardt","year":"2015","unstructured":"Leonhardt, S. et al. Trigger mechanisms of secondary sclerosing cholangitis in critically ill patients. Crit. Care 19, 131 (2015).","journal-title":"Crit. Care"},{"key":"73948_CR21","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.cld.2015.08.009","volume":"20","author":"SV Beath","year":"2016","unstructured":"Beath, S. V. & Kelly, D. A. Total parenteral nutrition-induced cholestasis: Prevention and management. Clin. Liver Dis. 20, 159\u2013176 (2016).","journal-title":"Clin. Liver Dis."},{"key":"73948_CR22","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/ncp.10461","volume":"35","author":"H Madnawat","year":"2020","unstructured":"Madnawat, H. et al. Mechanisms of parenteral nutrition-associated liver and gut injury. Nutr. Clin. Pract. 35, 63\u201371 (2020).","journal-title":"Nutr. Clin. Pract."},{"key":"73948_CR23","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13054-022-04019-8","volume":"26","author":"PD Wendel-Garcia","year":"2022","unstructured":"Wendel-Garcia, P. D. et al. Long-term ketamine infusion-induced cholestatic liver injury in COVID-19-associated acute respiratory distress syndrome. Crit. Care 26, 148 (2022).","journal-title":"Crit. Care"},{"key":"73948_CR24","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s00134-021-06482-3","volume":"47","author":"C de Tymowski","year":"2021","unstructured":"de Tymowski, C., D\u00e9pret, F., Dudoignon, E., Legrand, M. & Mallet, V. Ketamine-induced cholangiopathy in ARDS patients. Intensive Care Med. 47, 1173\u20131174 (2021).","journal-title":"Intensive Care Med."},{"key":"73948_CR25","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1007\/s00134-023-07257-8","volume":"49","author":"S Leonhardt","year":"2023","unstructured":"Leonhardt, S., Baumann, S., J\u00fcrgensen, C., H\u00fcter, L. & Leonhardt, J. Role of intravenous ketamine in the pathogenesis of secondary sclerosing cholangitis in critically ill patients: Perpetrator or innocent bystander? Answers provided by forensic toxicology. Intensive Care Med. 49, 1549\u20131551 (2023).","journal-title":"Intensive Care Med."},{"key":"73948_CR26","first-page":"2526","volume":"307","author":"VM Ranieri","year":"2012","unstructured":"Ranieri, V. M. et al. Acute respiratory distress syndrome the berlin definition. JAMA 307, 2526\u20132533 (2012).","journal-title":"JAMA"},{"key":"73948_CR27","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1038\/ajg.2010.216","volume":"105","author":"T Kumagi","year":"2010","unstructured":"Kumagi, T. et al. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am. J. Gastroenterol. 105, 2186\u20132194 (2010).","journal-title":"Am. J. Gastroenterol."},{"key":"73948_CR28","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1002\/hep.32582","volume":"76","author":"L Hartl","year":"2022","unstructured":"Hartl, L. et al. Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID-19 in patients with chronic liver disease. Hepatology 76, 1563\u20131575 (2022).","journal-title":"Hepatology"},{"key":"73948_CR29","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.jhep.2020.05.002","volume":"73","author":"YJ Wang","year":"2020","unstructured":"Wang, Y. J. et al. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. J. Hepatol. 73, 807\u2013816 (2020).","journal-title":"J. Hepatol."},{"key":"73948_CR30","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00011-020-01401-6","volume":"69","author":"T Iba","year":"2020","unstructured":"Iba, T., Connors, J. M. & Levy, J. H. The coagulopathy, endotheliopathy, and vasculitis of COVID-19. Inflamm. Res. 69, 1181\u20131189 (2020).","journal-title":"Inflamm. Res."},{"key":"73948_CR31","doi-asserted-by":"publisher","first-page":"350","DOI":"10.7326\/M20-2566","volume":"173","author":"SF Lax","year":"2020","unstructured":"Lax, S. F. et al. Pulmonary arterial thrombosis in COVID-19 with fatal outcome: Results from a prospective, single-center, clinicopathologic case series. Ann. Intern. Med. 173, 350\u2013361 (2020).","journal-title":"Ann. Intern. Med."},{"key":"73948_CR32","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1056\/NEJM199810223391707","volume":"339","author":"M Trauner","year":"1998","unstructured":"Trauner, M., Meier, P. J. & Boyer, J. L. Molecular pathogenesis of cholestasis. N. Engl. J. Med. 339, 1217\u20131227 (1998).","journal-title":"N. Engl. J. Med."},{"key":"73948_CR33","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1152\/physrev.00027.2002","volume":"83","author":"M Trauner","year":"2003","unstructured":"Trauner, M. & Boyer, J. L. Bile salt transporters: Molecular characterization, function, and regulation. Physiol. Rev. 83, 633\u2013671 (2003).","journal-title":"Physiol. Rev."},{"key":"73948_CR34","doi-asserted-by":"publisher","first-page":"3497","DOI":"10.1002\/hep.32027","volume":"74","author":"N Vartak","year":"2021","unstructured":"Vartak, N. et al. On the mechanisms of biliary flux. Hepatology 74, 3497\u20133512 (2021).","journal-title":"Hepatology"},{"key":"73948_CR35","doi-asserted-by":"crossref","unstructured":"Harnisch, L. O. et al. Biomarkers of cholestasis and liver injury in the early phase of acute respiratory distress syndrome and their pathophysiological value. Diagnostics 11, (2021).","DOI":"10.3390\/diagnostics11122356"},{"key":"73948_CR36","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.jhep.2019.05.009","volume":"71","author":"C de Tymowski","year":"2019","unstructured":"de Tymowski, C. et al. Contributing factors and outcomes of burn-associated cholestasis. J. Hepatol. 71, 563\u2013572 (2019).","journal-title":"J. Hepatol."},{"key":"73948_CR37","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/nrgastro.2009.46","volume":"6","author":"P Ruemmele","year":"2009","unstructured":"Ruemmele, P., Hofstaedter, F. & Gelbmann, C. M. Secondary sclerosing cholangitis. Nat. Rev. Gastroenterol. Hepatol. 6, 287\u2013295 (2009).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"73948_CR38","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/2047-783X-17-30","volume":"17","author":"T Weig","year":"2012","unstructured":"Weig, T. et al. Abdominal obesity and prolonged prone positioning increase risk of developing sclerosing cholangitis in critically ill patients with influenza A-associated ARDS. Eur. J. Med. Res. 17, 30 (2012).","journal-title":"Eur. J. Med. Res."},{"key":"73948_CR39","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1016\/j.cgh.2014.01.041","volume":"12","author":"GL Wong","year":"2014","unstructured":"Wong, G. L. et al. Liver injury is common among chronic abusers of ketamine. Clin. Gastroenterol. Hepatol. 12, 1759\u20131762e1751 (2014).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"73948_CR40","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.jhep.2020.12.012","volume":"74","author":"ZY Ding","year":"2021","unstructured":"Ding, Z. Y. et al. Association of liver abnormalities with in-hospital mortality in patients with COVID-19. J. Hepatol. 74, 1295\u20131302 (2021).","journal-title":"J. Hepatol."},{"key":"73948_CR41","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1111\/liv.15274","volume":"42","author":"L Hartl","year":"2022","unstructured":"Hartl, L. et al. Age-adjusted mortality and predictive value of liver chemistries in a viennese cohort of COVID-19 patients. Liver Int. 42, 1297\u20131307 (2022).","journal-title":"Liver Int."},{"key":"73948_CR42","doi-asserted-by":"publisher","first-page":"570","DOI":"10.3748\/wjg.v28.i5.570","volume":"28","author":"A Krishnan","year":"2022","unstructured":"Krishnan, A. et al. Abnormal liver chemistries as a predictor of COVID-19 severity and clinical outcomes in hospitalized patients. World J. Gastroenterol. 28, 570\u2013587 (2022).","journal-title":"World J. Gastroenterol."},{"key":"73948_CR43","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1097\/01.CCM.0000259462.97164.A0","volume":"35","author":"L Kramer","year":"2007","unstructured":"Kramer, L., Jordan, B., Druml, W., Bauer, P. & Metnitz, P. G. Incidence and prognosis of early hepatic dysfunction in critically ill patients\u2014A prospective multicenter study. Crit. Care Med. 35, 1099\u20131104 (2007).","journal-title":"Crit. Care Med."},{"key":"73948_CR44","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1046\/j.1365-2036.1999.00596.x","volume":"13","author":"M Trauner","year":"1999","unstructured":"Trauner, M. & Graziadei, I. W. Review article: Mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases. Aliment. Pharmacol. Ther. 13, 979\u2013996 (1999).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"73948_CR45","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1016\/j.jhep.2015.02.023","volume":"62","author":"U Beuers","year":"2015","unstructured":"Beuers, U., Trauner, M., Jansen, P. & Poupon, R. New paradigms in the treatment of hepatic cholestasis: From UDCA to FXR, PXR and beyond. J. Hepatol. 62, S25\u201337 (2015).","journal-title":"J. Hepatol."},{"key":"73948_CR46","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1177\/08971900211038363","volume":"36","author":"K Al Sulaiman","year":"2023","unstructured":"Al Sulaiman, K. et al. Impact of ursodeoxycholic acid in critically ill patients with sepsis: A retrospective study. J. Pharm. Pract. 36, 566\u2013571 (2023).","journal-title":"J. Pharm. Pract."},{"key":"73948_CR47","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","volume":"67","author":"EASL Clinical Practice Guidelines","year":"2017","unstructured":"EASL Clinical Practice Guidelines. The diagnosis and management of patients with primary biliary cholangitis. J. Hepatol. 67, 145\u2013172 (2017).","journal-title":"J. Hepatol."},{"key":"73948_CR48","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.jhep.2022.05.011","volume":"77","author":"EASL Clinical Practice","year":"2022","unstructured":"EASL Clinical Practice. Guidelines on sclerosing cholangitis. J. Hepatol. 77, 761\u2013806 (2022).","journal-title":"J. Hepatol."},{"key":"73948_CR49","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.14309\/ajg.0000000000000557","volume":"115","author":"CF Murillo Perez","year":"2020","unstructured":"Murillo Perez, C. F. et al. Goals of treatment for improved survival in primary biliary cholangitis: Treatment target should be bilirubin within the normal range and normalization of alkaline phosphatase. Am. J. Gastroenterol. 115, 1066\u20131074 (2020).","journal-title":"Am. J. Gastroenterol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-73948-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-73948-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-73948-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T08:03:12Z","timestamp":1728633792000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-73948-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,8]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["73948"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-73948-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,8]]},"assertion":[{"value":"16 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"M.T. received speaker fees from BMS, Falk Foundation, Gilead, Intercept, Ipsen, Jannsen, Madrigal, MSD and Roche; he advised for Abbvie, Agomab, Albireo, BiomX, Boehringer Ingelheim, Chemomab, Cymabay, Falk Pharma GmbH, Genfit, Gilead, Hightide, Intercept, Janssen, LoopLab, Mirum, MSD, Novartis, Phenex, Pliant, Rectify, Regulus, Siemens and Shire. He further received travel support from Abbvie, Falk, Gilead, Intercept and Jannsen and research grants from Albireo, Alnylam, Cymabay, Falk, Genentech, Gilead, Intercept, MSD, Takeda and UltraGenyx. He is also co-inventor of patents on the medical use of norUDCA filed by the Medical Universities of Graz and Vienna. K.K. received research grants from Apeptico, Biotest, Bayer and Alterras and travel support from Biotest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests outside the submitted work"}},{"value":"The study was approved by the local Ethics Committee of the Medical University of Vienna (EK 1872\/2021). Given the retrospective design of the study, informed consent statements are not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and informed consent"}}],"article-number":"23377"}}